[ 1 ] Hui DS, Azhar EI, Kim YJ, Memish ZA, Oh MD, Zumla A. Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission. Lancet Infect Dis 2018;18(8):e217–27. link1

[ 2 ] Lee H, Lei H, Santarsiero BD, Gatuz JL, Cao S, Rice AJ, et al. Inhibitor recognition specificity of MERS-CoV papain-like protease may differ from that of SARSCoV. ACS Chem Biol 2015;10(6):1456–65. link1

[ 3 ] Choi J, Kim MG, Oh YK, Kim YB. Progress of Middle East respiratory syndrome coronavirus vaccines: a patent review. Expert Opin Ther Pat 2017;27 (6):721–31. link1

[ 4 ] Zaki AM, Van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012;367(19):1814–20. link1

[ 5 ] Pallesen J, Wang N, Corbett KS, Wrapp D, Kirchdoerfer RN, Turner HL, et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc Natl Acad Sci USA 2017;114(35):E7348–57. link1

[ 6 ] Beigel JH, Voell J, Kumar P, Raviprakash K, Wu H, Jiao JA, et al. Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study. Lancet Infect Dis 2018;18(4):410–8. link1

[ 7 ] Van Boheemen S, De Graaf M, Lauber C, Bestebroer TM, Raj VS, Zaki AM, et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio 2012;3(6):e00473–512. link1

[ 8 ] Frey KG, Redden CL, Bishop-Lilly KA, Johnson R, Hensley LE, Raviprakash K, et al. Full-genome sequence of human betacoronavirus 2c Jordan-N3/2012 after serial passage in mammalian cells. Genome Announc 2014;2(3): e00324–414. link1

[ 9 ] Chan JF, Lau SK, To KK, Cheng VC, Woo PC, Yuen KY. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease. Clin Microbiol Rev 2015;28(2):465–522. link1

[10] Cotten M, Lam TT, Watson SJ, Palser AL, Petrova V, Grant P, et al. Full-genome deep sequencing and phylogenetic analysis of novel human betacoronavirus. Emerg Infect Dis 2013;19(5):736–42. link1

[11] Widagdo W, Okba NMA, Stalin Raj V, Haagmans BL. MERS-coronavirus: from discovery to intervention. One Health 2016;3:11–6. link1

[12] Li F, Li W, Farzan M, Harrison SC. Structure of SARS coronavirus spike receptorbinding domain complexed with receptor. Science 2005;309(5742):1864–8. link1

[13] Du L, Kou Z, Ma C, Tao X, Wang L, Zhao G, et al. A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. PLoS One 2013;8(12):e81587. link1

[14] Lu G, Hu Y, Wang Q, Qi J, Gao F, Li Y, et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 2013;500 (7461):227–31. link1

[15] Ma C, Li Y, Wang L, Zhao G, Tao X, Tseng CT, et al. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: implication for designing novel mucosal MERS vaccines. Vaccine 2014;32(18):2100–8. link1

[16] Mou H, Raj VS, Van Kuppeveld FJ, Rottier PJ, Haagmans BL, Bosch BJ. The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. J Virol 2013;87(16):9379–83. link1

[17] Lan J, Yao Y, Deng Y, Hu Y, Bao L, Huang B, et al. The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection. Vaccine 2017;35(1):10–8. link1

[18] Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet 2015;386(9997):995–1007. link1

[19] Lu L, Liu Q, Zhu Y, Chan KH, Qin L, Li Y, et al. Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun 2014;5:3067. link1

[20] Millet JK, Whittaker GR. Host cell proteases: critical determinants of coronavirus tropism and pathogenesis. Virus Res 2015;202:120–34. link1

[21] Lu G, Wang Q, Gao GF. Bat-to-human: spike features determining ‘‘host jump” of coronaviruses SARS-CoV, MERS-CoV, and beyond. Trends Microbiol 2015;23 (8):468–78. link1

[22] Surya W, Li Y, Verdià-Bàguena C, Aguilella VM, Torres J. MERS coronavirus envelope protein has a single transmembrane domain that forms pentameric ion channels. Virus Res 2015;201:61–6. link1

[23] Westerbeck JW, Machamer CE. A coronavirus E protein is present in two distinct pools with different effects on assembly and the secretory pathway. J Virol 2015;89(18):9313–23. link1

[24] Xie Q, He X, Yang F, Liu X, Li Y, Liu Y, et al. Analysis of the genome sequence and prediction of B-cell epitopes of the envelope protein of Middle East respiratory syndrome-coronavirus. IEEE/ACM Trans Comput Biol Bioinform 2018;15(4):1344–50. link1

[25] Liu J, Sun Y, Qi J, Chu F, Wu H, Gao F, et al. The membrane protein of severe acute respiratory syndrome coronavirus acts as a dominant immunogen revealed by a clustering region of novel functionally and structurally defined cytotoxic T-lymphocyte epitopes. J Infect Dis 2010;202(8):1171–80. link1

[26] De Haan CA, Rottier PJ. Molecular interactions in the assembly of coronaviruses. Adv Virus Res 2005;64:165–230. link1

[27] Lin SC, Ho CT, Chuo WH, Li S, Wang TT, Lin CC. Effective inhibition of MERSCoV infection by resveratrol. BMC Infect Dis 2017;17(1):144. link1

[28] Szelazek B, Kabala W, Kus K, Zdzalik M, Twarda-Clapa A, Golik P, et al. Structural characterization of human coronavirus NL63 N protein. J Virol 2017;91(11):e02503–16. link1

[29] Hu Y, Li W, Gao T, Cui Y, Jin Y, Li P, et al. The severe acute respiratory syndrome coronavirus nucleocapsid inhibits type I interferon production by interfering with TRIM25-mediated RIG-I ubiquitination. J Virol 2017;91(8): e02143–16. link1

[30] Grunewald ME, Fehr AR, Athmer J, Perlman S. The coronavirus nucleocapsid protein is ADP-ribosylated. Virology 2018;517:62–8. link1

[31] Papageorgiou N, Lichière J, Baklouti A, Ferron F, Sévajol M, Canard B, et al. Structural characterization of the N-terminal part of the MERS-CoV nucleocapsid by X-ray diffraction and small-angle X-ray scattering. Acta Crystallogr D Struct Biol 2016;72(Pt 2):192–202. link1

[32] Banda NK, Acharya S, Scheinman RI, Mehta G, Takahashi M, Endo Y, et al. Deconstructing the lectin pathway in the pathogenesis of experimental inflammatory arthritis: essential role of the lectin ficolin B and mannosebinding protein-associated serine protease 2. J Immunol 2017;199 (5):1835–45. link1

[33] Bolwig GM, Bruder JT, Hearing P. Different binding site requirements for binding and activation for the bipartite enhancer factor EF-1A. Nucleic Acids Res 1992;20(24):6555–64. link1

[34] Forni D, Cagliani R, Clerici M, Sironi M. Molecular evolution of human coronavirus genomes. Trends Microbiol 2017;25(1):35–48. link1

[35] Menachery VD, Mitchell HD, Cockrell AS, Gralinski LE, Yount BL Jr, Graham RL, et al. MERS-CoV accessory ORFs play key role for infection and pathogenesis. MBio 2017;8(4):e00665–717. link1

[36] Yang Y, Zhang L, Geng H, Deng Y, Huang B, Guo Y, et al. The structural and accessory proteins M, ORF 4a, ORF 4b, and ORF 5 of Middle East respiratory syndrome coronavirus (MERS-CoV) are potent interferon antagonists. Protein Cell 2013;4(12):951–61. link1

[37] Thornbrough JM, Jha BK, Yount B, Goldstein SA, Li Y, Elliott R, et al. Middle East respiratory syndrome coronavirus NS4b protein inhibits host RNase L activation. MBio 2016;7(2):e00258. link1

[38] Rabouw HH, Langereis MA, Knaap RC, Dalebout TJ, Canton J, Sola I, et al. Middle East respiratory coronavirus accessory protein 4a inhibits PKR-mediated antiviral stress responses. PLoS Pathog 2016;12(10):e1005982. link1

[39] Zumla A, Chan JF, Azhar EI, Hui DS, Yuen KY. Coronaviruses—drug discovery and therapeutic options. Nat Rev Drug Discov 2016;15(5):327–47. link1

[40] Lei J, Kusov Y, Hilgenfeld R. Nsp3 of coronaviruses: structures and functions of a large multi-domain protein. Antiviral Res 2018;149:58–74. link1

[41] Báez-Santos YM, St John SE, Mesecar AD. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds. Antiviral Res 2015;115:21–38. link1

[42] Kankanamalage ACG, Kim Y, Damalanka VC, Rathnayake AD, Fehr AR, Mehzabeen N, et al. Structure-guided design of potent and permeable inhibitors of MERS coronavirus 3CL protease that utilize a piperidine moiety as a novel design element. Eur J Med Chem 2018;150:334–46. link1

[43] Kandeel M, Altaher A. Synonymous and biased codon usage by MERS CoV papain-like and 3CL-proteases. Biol Pharm Bull 2017;40(7):1086–91. link1

[44] Forni D, Cagliani R, Mozzi A, Pozzoli U, Al-Daghri N, Clerici M, et al. Extensive positive selection drives the evolution of nonstructural proteins in lineage C betacoronaviruses. J Virol 2016;90(7):3627–39. link1

[45] Oudshoorn D, Rijs K, Limpens RWAL, Groen K, Koster AJ, Snijder EJ, et al. Expression and cleavage of Middle East respiratory syndrome coronavirus nsp3-4 polyprotein induce the formation of double-membrane vesicles that mimic those associated with coronaviral RNA replication. MBio 2017;8(6): e01658–717. link1

[46] Terada Y, Kawachi K, Matsuura Y, Kamitani W. MERS coronavirus nsp1 participates in an efficient propagation through a specific interaction with viral RNA. Virology 2017;511:95–105. link1

[47] Zhang R, Li Y, Cowley TJ, Steinbrenner AD, Phillips JM, Yount BL, et al. The nsp1, nsp13, and M proteins contribute to the hepatotropism of murine coronavirus JHM.WU. J Virol 2015;89(7):3598–609. link1

[48] Adedeji AO, Lazarus H. Biochemical characterization of Middle East respiratory syndrome coronavirus helicase. mSphere 2016;1(5):e00235–316. link1

[49] Kindler E, Gil-Cruz C, Spanier J, Li Y, Wilhelm J, Rabouw HH, et al. Early endonuclease-mediated evasion of RNA sensing ensures efficient coronavirus replication. PLoS Pathog 2017;13(2):e1006195. link1

[50] Deng X, HackbartM,Mettelman RC, O’Brien A,Mielech AM, Yi G, et al. Coronavirus nonstructural protein 15 mediates evasion of dsRNA sensors and limits apoptosis in macrophages. Proc Natl Acad Sci USA 2017;114(21):E4251–60. link1

[51] Aouadi W, Blanjoie A, Vasseur JJ, Debart F, Canard B, Decroly E. Binding of the methyl donor S-adenosyl-I-methionine to Middle East respiratory syndrome coronavirus 20 -O-methyltransferase nsp16 promotes recruitment of the allosteric activator nsp10. J Virol 2017;91(5):e02217–316. link1

[52] Angelini MM, Akhlaghpour M, Neuman BW, Buchmeier MJ. Severe acute respiratory syndrome coronavirus nonstructural proteins 3, 4, and 6 induce double-membrane vesicles. MBio 2013;4(4):e00524–613. link1

[53] Menachery VD, Gralinski LE, Mitchell HD, Dinnon KH 3rd, Leist SR, Yount BL Jr, et al. Middle East respiratory syndrome coronavirus nonstructural protein 16 is necessary for interferon resistance and viral pathogenesis. mSphere 2017;2 (6):e00346–417. link1

[54] Alfuwaires M, Altaher A, Kandeel M. Molecular dynamic studies of interferon and innate immunity resistance in MERS CoV Non-Structural Protein 3. Biol Pharm Bull 2017;40(3):345–51. link1

[55] Huang YP, Cho CC, Chang CF, Hsu CH. NMR assignments of the macro domain from Middle East respiratory syndrome coronavirus (MERS-CoV). Biomol NMR Assign 2016;10(2):245–8. link1

[56] Phua KKL, Liu Y, Sim SH. Non-linear enhancement of mRNA delivery efficiencies by influenza A derived NS1 protein engendering host gene inhibition property. Biomaterials 2017;133:29–36. link1

[57] Qian W, Wei X, Guo K, Li Y, Lin X, Zou Z, et al. The C-terminal effector domain of non-structural protein 1 of influenza A virus blocks IFN-b production by targeting TNF receptor-associated factor 3. Front Immunol 2017;8:779. link1

[58] Kuo RL, Li LH, Lin SJ, Li ZH, Chen GW, Chang CK, et al. Role of N terminustruncated NS1 proteins of influenza A virus in inhibiting IRF3 activation. J Virol 2016;90(9):4696–705. link1

[59] Schierhorn KL, Jolmes F, Bespalowa J, Saenger S, Peteranderl C, Dzieciolowski J, et al. Influenza a virus virulence depends on two amino acids in the N-terminal domain of its NS1 protein to facilitate inhibition of the RNA-dependent protein kinase PKR. J Virol 2017;91(10):e00198–217. link1

[60] Lokugamage KG, Narayanan K, Nakagawa K, Terasaki K, Ramirez SI, Tseng CT, et al. Middle East respiratory syndrome coronavirus nsp1 inhibits host gene expression by selectively targeting mRNAs transcribed in the nucleus while sparing mRNAs of cytoplasmic origin. J Virol 2015;89(21):10970–81. link1

[61] Peters HL, Jochmans D, de Wilde AH, Posthuma CC, Snijder EJ, Neyts J, et al. Design, synthesis and evaluation of a series of acyclic fleximer nucleoside analogues with anti-coronavirus activity. Bioorg Med Chem Lett 2015;25 (15):2923–6. link1

[62] Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J, et al. Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother 2014;58(8):4885–93. link1

[63] De Wilde AH, Raj VS, Oudshoorn D, Bestebroer TM, Van Nieuwkoop S, Limpens RW, et al. MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-a treatment. J Gen Virol 2013;94(Pt 8):1749–60. link1

[64] Mustafa S, Balkhy H, Gabere MN. Current treatment options and the role of peptides as potential therapeutic components for Middle East Respiratory Syndrome (MERS): a review. J Infect Public Health 2018;11(1):9–17. link1

[65] Kim YS, Son A, Kim J, Kwon SB, Kim MH, Kim P, et al. Chaperna-mediated assembly of ferritin-based Middle East respiratory syndrome-coronavirus nanoparticles. Front Immunol 2018;9:1093. link1

[66] Corti D, Passini N, Lanzavecchia A, Zambon M. Rapid generation of a human monoclonal antibody to combat Middle East respiratory syndrome. J Infect Public Health 2016;9(3):231–5. link1

[67] Tang XC, Agnihothram SS, Jiao Y, Stanhope J, Graham RL, Peterson EC, et al. Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc Natl Acad Sci USA 2014;111(19): E2018–26. link1

[68] Jiang L, Wang N, Zuo T, Shi X, Poon KM, Wu Y, et al. Potent neutralization of MERS-CoV by human neutralizing monoclonal antibodies to the viral spike glycoprotein. Sci Transl Med 2014;6(234):234ra59. link1

[69] Niu P, Zhang S, Zhou P, Huang B, Deng Y, Qin K, et al. Ultrapotent human neutralizing antibody repertoires against Middle East respiratory syndrome coronavirus from a recovered patient. J Infect Dis 2018;218(8):1249–60. link1

[70] Pascal KE, Coleman CM, Mujica AO, Kamat V, Badithe A, Fairhurst J, et al. Preand postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection. Proc Natl Acad Sci USA 2015;112(28):8738–43. link1

[71] De Wit E, Feldmann F, Okumura A, Horne E, Haddock E, Saturday G, et al. Prophylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosets. Antiviral Res 2018;156:64–71. link1

[72] Du L, Zhao G, Yang Y, Qiu H, Wang L, Kou Z, et al. A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein. J Virol 2014;88(12):7045–53. link1

[73] Rabaan AA, Alahmed SH, Bazzi AM, Alhani HM. A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective. J Med Microbiol 2017;66(9):1261–74. link1

[74] Qiu H, Sun S, Xiao H, Feng J, Guo Y, Tai W, et al. Single-dose treatment with a humanized neutralizing antibody affords full protection of a human transgenic mouse model from lethal Middle East respiratory syndrome (MERS)- coronavirus infection. Antiviral Res 2016;132:141–8. link1

[75] Li Y, Wan Y, Liu P, Zhao J, Lu G, Qi J, et al. A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein. Cell Res 2015;25(11):1237–49. link1

[76] Zhang N, Channappanavar R, Ma C, Wang L, Tang J, Garron T, et al. Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus. Cell Mol Immunol 2016;13(2):180–90. link1

[77] Wang L, Shi W, Joyce MG, Modjarrad K, Zhang Y, Leung K, et al. Evaluation of candidate vaccine approaches for MERS-CoV. Nat Commun 2015;6:7712. link1

[78] Shirato K, Kawase M, Matsuyama S. Middle East respiratory syndrome coronavirus infection mediated by the transmembrane serine protease TMPRSS2. J Virol 2013;87(23):12552–61. link1

[79] Gierer S, Bertram S, Kaup F, Wrensch F, Heurich A, Krämer-Kühl A, et al. The spike protein of the emerging betacoronavirus EMC uses a novel coronavirus receptor for entry, can be activated by TMPRSS2, and is targeted by neutralizing antibodies. J Virol 2013;87(10):5502–11. link1

[80] Millet JK, Whittaker GR. Host cell entry of Middle East respiratory syndrome coronavirus after two-step, furin-mediated activation of the spike protein. Proc Natl Acad Sci USA 2014;111(42):15214–9. link1

[81] Coleman CM, Sisk JM, Mingo RM, Nelson EA, White JM, Frieman MB. Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus fusion. J Virol 2016;90(19):8924–33. link1

[82] Wrensch F, Winkler M, Pöhlmann S. IFITM proteins inhibit entry driven by the MERS-coronavirus spike protein: evidence for cholesterol-independent mechanisms. Viruses 2014;6(9):3683–98. link1

[83] Liu S, Wu S, Jiang S. HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds. Curr Pharm Des 2007;13 (2):143–62. link1

[84] Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol 2015;1282:1–23. link1

[85] Kirchdoerfer RN, Cottrell CA, Wang N, Pallesen J, Yassine HM, Turner HL, et al. Pre-fusion structure of a human coronavirus spike protein. Nature 2016;531 (7592):118–21. link1

[86] Walls AC, Tortorici MA, Frenz B, Snijder J, Li W, Rey FA, et al. Glycan shield and epitope masking of a coronavirus spike protein observed by cryo-electron microscopy. Nat Struct Mol Biol 2016;23(10): 899–905. link1

[87] Walls A, Tortorici MA, Bosch BJ, Frenz B, Rottier PJ, DiMaio F, et al. Crucial steps in the structure determination of a coronavirus spike glycoprotein using cryoelectron microscopy. Protein Sci 2017;26(1):113–21. link1

[88] Gao X, Zhou H, Wu C, Xiao Y, Ren L, Paranhos-Baccalà G, et al. Antibody against nucleocapsid protein predicts susceptibility to human coronavirus infection. J Infect 2015;71(5):599–602. link1

[89] Yamaoka Y, Matsuyama S, Fukushi S, Matsunaga S, Matsushima Y, Kuroyama H, et al. Development of monoclonal antibody and diagnostic test for Middle East respiratory syndrome coronavirus using cell-free synthesized nucleocapsid antigen. Front Microbiol 2016;7:50. link1